Cohance Lifesciences Invests $18M in NJ Bio and Aruka Bio to Advance ADC Strategy
Cohance Lifesciences Ltd 路 Press Release 路 04 Sept 2026, 1:40 am
Cohance Lifesciences Invests $18M in NJ Bio and Aruka Bio to Advance ADC Strategy Cohance Lifesciences will invest $18M via internal accruals to strengthen its Antibody-Drug Conjugate (ADC) strategy, expecting completion by Sep'26. A $13M allocation increases Cohance's equity in NJ Bio from 56.0% to 67.3%, integrating NJ Bio's CRDMO services with Cohance's commercial manufacturing. The remaining $5M secures a controlling 65% stake in Aruka Bio, making the preclinical ADC developer a direct subsidiary. This reorganization distinctly separates NJ Bio's customer-facing commercial operations from Aruka's proprietary drug pipeline development, positioning Aruka for future licensing partnerships.
Original exchange filing (PDF)
More announcements from Cohance Lifesciences Ltd
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings .... 路 12 Nov 2026
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 12 Nov 2026
- Investors Meet 路 11 Nov 2026
- Transcript of Con call 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & Others 路 11 Nov 2026
- Investor Presentation 路 07 Nov 2026
- Update on USFDA inspection at Pashamylaram Manufacturing facility. 路 07 Nov 2026
